---
name: Charles River Cell & Gene Therapy
slug: criver
site: cdmo
website_domain: criver.com
summary: Charles River Cell & Gene Therapy provides CDMO services. Headquartered in United States.
tagline: Supporting drug development from discovery through commercialization with integrated services and CGMP manufacturing.
founded_year: 
employee_count_band: 5001+
employee_count_label: 5,001+
parent_name: 
parent_slug: 
hq_country: US
tier2_domain_verified: false
updated_at: 2026-06-06T19:29:03.403Z
services_count: 21
modalities_count: 6
indications_count: 3
locations_count: 1
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Charles River Cell & Gene Therapy

Supporting drug development from discovery through commercialization with integrated services and CGMP manufacturing.

Listed on cdmo.directory.

## Summary

Charles River Cell & Gene Therapy provides CDMO services. Headquartered in United States.

## At a glance

- Employees (est.): 5,001+
- HQ country: US

## Services

- Sterile Fill-Finish & Aseptic Manufacturing
- Lentiviral Vector Manufacturing
- AAV Manufacturing
- Small Molecule Development & Manufacturing
- Microbial Fermentation
- Cell-Line Development
- Stability Testing & Storage
- CMC Analytical Development
- Downstream Processing
- Upstream Processing
- API Synthesis & Manufacturing
- Biologics Development & Manufacturing
- Monoclonal Antibody (mAb) Manufacturing
- Recombinant Protein Manufacturing
- Viral Vector Manufacturing
- Cell Therapy Manufacturing
- Process Development
- Formulation Development
- Technology Transfer
- Quality Control Testing
- CMC Regulatory Submission Support

## Modalities

- AAV / Viral Vector Platform
- Small Molecule
- Biologics (Other)
- Biologics (Monoclonal Antibodies)
- Cell Therapy
- Gene Therapy

## Indications

- Immunology
- Neurology
- Oncology

## Locations

- Headquarters, United States

## Certifications

- PMDA; Identifier: Retrogenix® platform data support; Source: https://criver.com/
- EMA; Identifier: Retrogenix® platform data support; Source: https://criver.com/
- PMDA; Identifier: 100 IND submissions containing Retrogenix® platform data; Source: https://criver.com/
- EMA; Identifier: 100 IND submissions containing Retrogenix® platform data; Source: https://criver.com/
- FDA; Identifier: 100 IND submissions containing Retrogenix® platform data; Source: https://criver.com/

## Long description

Charles River Laboratories operates a comprehensive drug development and manufacturing platform spanning basic research, discovery, preclinical testing, clinical development, and manufacturing and commercialization. The company provides integrated drug discovery services that reduce time to clinic by up to a year, combining target discovery, hit identification, hit-to-lead, lead optimization, safety, and toxicology under unified project management across therapeutic areas including oncology, neuroscience, and immunology.

The Cell and Gene CDMO division offers end-to-end scalable solutions from early-stage research and testing through commercial release. Biologics testing and manufacturing services support the full biologic development cycle with CGMP-compliant contract manufacturing. The company provides microbiology quality control solutions for contamination control and production acceleration, alongside rapid and compliant microbial testing to optimize QC workflows.

Charles River supports IND-enabling programs with expertise across major therapeutic areas, including medical devices and gene and cell therapies. The company offers scientific and regulatory advisory services to navigate the changing regulatory landscape for pharmaceuticals, industrial chemicals, pesticides, and food/feed applications. One Step Manufacturing provides a comprehensive suite of CRO services in target discovery, lead optimization, development chemistry, GMP, drug product development, and CMC strategy. Fast Lane Paradigm helps expedite IND applications by reducing white space between studies.

The organization has supported 80% of FDA-approved drugs over the past five years and conducted 1,500 IND studies in the last 12 months. It has generated 100 IND submissions containing Retrogenix® platform data supported across FDA, EMA, and PMDA regulatory bodies. Charles River is a 2024 signatory of the United Nations Global Compact and achieved 100% renewable electricity in 2024.

_Profile last updated: 2026-06-06T19:29:03.403Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.